(Lymphoma) Is Anti-ROR1 Antibody Zilovertamab Vedotin Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- November 1, 2021
- Read time: 1 minute
On October 12, 2021, Michael L. Wang et al. of MD Anderson Cancer Center published in The New England Journal of Medicine the efficacy and safety validation results of anti-ROR1 antibody drug Zilovertamab vedotin in a Phase 1 clinical trial in heavily pretreated malignant lymphoma patients.
This Phase 1 clinical trial administered Zilovertamab vedotin monotherapy (3-week cycle, doses of 0.5, 1.0, 1.5, 2.25, 2.5 mg/kg) to heavily pretreated malignant lymphoma patients (N=32) until unacceptable adverse events occurred. The primary endpoint was maximum tolerated dose, and the secondary endpoint was objective response rate.
Patients enrolled in this trial included 15 with mantle cell lymphoma, 7 with chronic lymphocytic leukemia, 5 with diffuse large B-cell lymphoma, and 3 with follicular lymphoma. The median number of prior treatment regimens was four.
Trial results showed that confirmed adverse events were acute neutropenia and neuropathy, with no clinically relevant adverse events identified. Based on these results, the recommended dose of Zilovertamab vedotin was determined to be 2.5 mg/kg every 3 weeks.
The secondary endpoint objective response rate was: mantle cell lymphoma 47% (N=7/15), diffuse large B-cell lymphoma 60% (N=3/5). No antitumor activity was confirmed in other malignant lymphomas.
Based on the Phase 1 clinical trial results, Michael L. Wang et al. stated: In heavily pretreated malignant lymphoma patients, anti-ROR1 antibody drug Zilovertamab vedotin was well tolerated. Antitumor activity in mantle cell lymphoma and diffuse large B-cell lymphoma met clinical expectations, and targeting ROR1 may provide a new clinically beneficial approach.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4